Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Provigil modafinil: Phase II; marketed to treat excessive daytime sleepiness (EDS) associated with narcolepsy

In a 22-patient U.S. cross-over study comparing Provigil to dextroamphetamine and

Read the full 113 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE